Reproducibility of pre-clinical research

From Cancer research in crisis: Are the drugs we count on based on bad science?

Scientists at the biotechnology company Amgen were unable to replicate the vast majority of published pre-clinical research studies. Only 6 out of 53 landmark cancer studies could be replicated, a dismal success rate of 11%.    .......  Unfortunately, the Amgen scientists were bound by confidentiality agreements that they had entered into with the scientists whose work they attempted to replicate. They could not reveal which papers were irreproducible or specific details regarding the experiments, thus leaving the cancer research world in a state of uncertainty. If so much published cancer research cannot be replicated, how can the field progress?

and

Some of the most highly cited papers in stem cell biology cannot be replicated [AH1] , and a recent clinical trial using bone marrow cells to regenerate the heart did not succeed in improving heart function after a heart attack [AH2]  despite earlier trials demonstrating benefits.

f
Fortunately

The claims of low reproducibility made by Begley and Ellis, however, did not refer to clinical cancer research but to pre-clinical science. 

which means we can assume (hope?) the clinical trials of drugs and treatments has a higher degree of reproducibility.